July 21, 2017
SillaJen, Lee’s Pharmaceutical cleared for third phase testing cancer treatment Pexa-Vec
SillaJen and Lee’s Pharmaceutical Holdings have said that they’ve gotten the approval from the China Food and Drug Administration (CFDA) to get a Phase 3 clinical trial for advanced liver cancer using its oncolytic immunotherapy called Pexa-Vec, the PHOCUS study.